{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:28:23Z","timestamp":1747178903598,"version":"3.40.5"},"reference-count":69,"publisher":"Informa UK Limited","issue":"9","funder":[{"name":"Spanish Network for Research in Infectious Diseases","award":["REIPI RD16\/0016\/0003"],"award-info":[{"award-number":["REIPI RD16\/0016\/0003"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2020,6,12]]},"DOI":"10.1080\/14656566.2020.1739269","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T07:00:46Z","timestamp":1585206046000},"page":"1005-1013","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["An overview of ceftolozane sulfate + tazobactam for treating hospital acquired pneumonia"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8835-2702","authenticated-orcid":false,"given":"Ibai","family":"Los-Arcos","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Burgos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicen\u00e7","family":"Falc\u00f3","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benito","family":"Almirante","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,3,26]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1602581"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00582-2017"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-014-3239-2"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-561"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1447381"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S180905"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1086\/653053"},{"volume-title":"Surveillance of antimicrobial resistance in Europe \u2013 annual report of the European Antimicrobial Resistance Surveillance Network (EARSNet)","year":"2017","author":"European Centre for Disease Prevention and Control","key":"cit0010"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir934"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1186\/cc3995"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz149"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu219"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-17"},{"volume-title":"Presented at: IDWeek","year":"2017","author":"Kaye KS","key":"cit0016"},{"key":"cit0017","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.05927-11","volume-title":"In vitro activity of MK-7655, a novel \u03b2-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother.","author":"Hirsch EB","year":"2012"},{"key":"cit0018","unstructured":"Imipenem\/relebactam\/cilastatin versus piperacillin\/tazobactam for treatment of participants with bacterial pneumonia (MK- 7655A-014) (RESTORE-IMI 2) [Internet]. Identifier NCT02452047. [cited 2019 Dec 10]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02493764"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-017-3063-z"},{"key":"cit0020","unstructured":"Initial study of S-649266 for the treatment of nosocomial pneumonia caused by Gram-negative pathogens (APEKS-NP). Identifier NCT03032380. [cited 2019 Dec 10]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03032380"},{"key":"cit0021","doi-asserted-by":"crossref","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M, et al. Efficacy and safety of cefiderocol versus high-dose meropenem in patients with nosocomial pneumonia \u2013Results of a phase 3 randomized, multicenter, double-blind, non-inferiority study. Open Forum Infect Dis. 2019;6(Suppl 2):S994.","DOI":"10.1093\/ofid\/ofz415.2487"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1807634"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0168-2"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01350-17"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00031-19"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz283"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00160-19"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx009"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.01.032"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx136"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2019.00151"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky477"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.01.26"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.11.021"},{"key":"cit0036","doi-asserted-by":"crossref","first-page":"e02125","DOI":"10.1128\/AAC.00313-18","volume":"62","author":"Castanheira M","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00590-18"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00049-14"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ097"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01753-09"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06349-11"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.03.004"},{"key":"cit0043","first-page":"825","volume":"39","author":"Sorbera M","year":"2014","journal-title":"Pharm Ther"},{"key":"cit0044","first-page":"900","volume":"72","author":"Kullar R","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz416"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-018-3361-0"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.001"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1609"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01752-10"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02513-12"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00461-13"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks246"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.566"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.429"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30403-7"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01265-19"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01655-19"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1177\/0267659119864813"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02131-18"},{"journal-title":"Pediatr Crit Care Med","year":"2020","author":"Cies JJ","key":"cit0060"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix182"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy280"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz816"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62220-0"},{"key":"cit0065","unstructured":"[cited 2019 Dec 10]. Available from: https:\/\/investors.merck.com\/news\/press-release-details\/2019\/FDA-Approves-Mercks-ZERBAXA-ceftolozane-and-tazobactam-3g-Dose-for-the-Treatment-of-Adults-with-Hospital-Acquired-and-Ventilator-Associated-Bacterial-Pneumonia-HABPVABP\/default.aspx"},{"key":"cit0066","unstructured":"[cited 2019 Dec 10]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/zerbaxa-h-c-3772-ii-0020-epar-assessment-report-variation_en.pdf"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00875-17"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01858-17"},{"key":"cit0069","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dky425","volume":"74","author":"Hsueh SC","year":"2019","journal-title":"J Antimicrob Chemother"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2020.1739269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T20:02:14Z","timestamp":1666209734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2020.1739269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,26]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,6,12]]}},"alternative-id":["10.1080\/14656566.2020.1739269"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2020.1739269","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"type":"print","value":"1465-6566"},{"type":"electronic","value":"1744-7666"}],"subject":[],"published":{"date-parts":[[2020,3,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}